← brief for 2026-08-10 · Slowing decline

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Trial No results yet Not peer reviewed

Key takeaways

A large trial called EASi-KIDNEY is testing whether adding a new drug, BI 690517, to empagliflozin better protects the heart and kidneys in adults with chronic kidney disease. People with and without type 2 diabetes can join. There are no results yet.

Who did this work

Run by Boehringer Ingelheim.
Sites: Apogee Clinical Research · Southwest Kidney Institute · National Heart Institute · Florida Kidney Physicians LLC · Total Research Group, LLC · Emory University School of Medicine

Source

Trial registration · ClinicalTrials.gov — CKD recruiting · 2026-08-10
https://clinicaltrials.gov/study/NCT06531824